Impact of crizotinib on patient-reported symptoms and quality of life (QOL) compared with single-agent chemotherapy in a phase III study of advanced ALK+ non-small cell lung cancer (NSCLC).
Vera Hirsh
Consultant or Advisory Role - Pfizer
Fiona Helen Blackhall
Consultant or Advisory Role - Lilly (U); Pfizer (U)
Honoraria - Lilly; Pfizer
Research Funding - Lilly; Pfizer
Expert Testimony - Pfizer (U)
Other Remuneration - Lilly; Pfizer
Dong-Wan Kim
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Benjamin Besse
Consultant or Advisory Role - Pfizer (U)
Research Funding - Pfizer
Hiroshi Nokihara
No relevant relationships to disclose
Ji-Youn Han
No relevant relationships to disclose
Vanessa Roberts Tassell
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Arlene Reisman
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Shrividya Iyer
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Alice Tsang Shaw
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer